Pharming to nominate Fabrice Chouraqui as new CEO

21 January 2025

Dutch biotech Pharming Group (Euronext: PHARM) today announced that its board of directors has nominated Fabrice Chouraqui to become the company’s new executive director and chief executive, succeeding Sijmen de Vries.

Pharming will nominate Mr Chouraqui for the appointment for a term of four years at an upcoming Extraordinary General Meeting of Shareholders (EGM). Information regarding the EGM, including the notice to convene, will be shared shortly in a separate press release.

Upon the appointment of Mr Chouraqui, Sijmen de Vries will resign from the board of directors. To ensure a smooth hand-over of tasks and responsibilities, Mr de Vries will remain a strategic advisor to the new CEO until December 31, 2025.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology